Heart failure & cardiomyopathies
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
Authors' conclusion
In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2.4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype.
Study context
- Population
- Adults ≥45 years, BMI ≥27 kg/m², established CVD, with and without HF history (HFpEF, HFrEF, unclassified)4,286 (24.3%) with HF history
- Participants
- 17,604 adults
- Comparison
- Semaglutide 2.4 mg once weekly vs placebo, by HF history and subtype
- Semaglutiden = 8,803
- Placebon = 8,801reference
Methodological detailsprespecified analysis, double-blind, placebo-controlled, multicentre, event-driven, phase 3, 41 countries
- Prespecified analysis
- Double-blind
- Placebo-controlled
- Multicentre
- Event-driven
- Phase 3
- 41 countries
Primary result
As reported in the abstract
Semaglutide vs placebo in patients with HF at random assignment
Semaglutide vs PlaceboHazard ratio (95% CI)
MACE, HF
0.72(0.60–0.87)
HF composite endpoint, HF
0.79(0.64–0.98)
CV death, HF
0.76(0.59–0.97)
All-cause death, HF
0.81(0.66–1.00)
MACE, HFrEF
0.65(0.49–0.87)
Composite HF endpoint, HFrEF
0.79(0.58–1.08)
MACE, HFpEF
0.69(0.51–0.91)
Composite HF endpoint, HFpEF
0.75(0.52–1.07)
Further findings
Major adverse cardiovascular events (MACE) and HF composite, by baseline age, sex, BMI, NYHA status, diuretic use (subgroups)
- No significant differences in benefits across subgroups
Safety
Serious adverse events
- Less frequent with semaglutide vs placebo, regardless of HF subtype
Original publication
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. Published 24 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →